Advertisement

Investigational New Drugs

, Volume 10, Issue 3, pp 211–213 | Cite as

Phase II study of didemnin B in advanced colorectal cancer

  • Dennie V. JonesJr.
  • Jaffer A. Ajani
  • Roxann Blackburn
  • Karen Daugherty
  • Bernard Levin
  • Yehuda Z. Patt
  • James L. Abbruzzese
Clinical Studies

Summary

Didemnin B is a depsipeptide derived from a Caribbean tunicate (sea squirt) that has demonstrated antineoplastic activity against a variety of murine tumor models, including the L1210 and P388 leukemia, the B16 melanoma, and M5076 sarcoma cell lines. Based on these data, we designed a phase II trial in which 15 patients with measureable, unresectable colorectal cancer were treated with Didemnin B at an initial dosage of 3.47 mg/m2 over 30 minutes administered by intravenous infusion every 28 days; the dosage was altered in accordance with the toxicity observed, with only one patient requiring a dosage reduction for pronounced nausea and vomiting. No hematologie or nonhematologic toxicity developed. No complete or partial responses were observed. These results do not compare favorably with results of treatments using other single agents or combinations that are currently available for the treatment of advanced colorectal cancers. However, because of the tolerable levels of toxicity experienced by in our patients, it is possible that an insufficient dose of the medication was delivered. We concluded that Didemnin B is not active against of colorectal cancers at the dosage and schedule at which it was administered in this study.

Key words

didemnin B colorectal cancer 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cohen A, Shank B, Friedman M: Colorectal cancer. In: DeVita V, Hellman S, Rosenberg S (eds.) Cancer: Principles and practice of oncology, Third Edition. J.B. Lippincott, Co., Philadelphia, 1989, pp 895–964Google Scholar
  2. 2.
    Rinehart K, Gloer J, Wilson G, Hughes R, Li L, Renis H, McGovren J: Antiviral and antitumor compounds from tunicates. Federation Proceedings 42:87–90, 1983PubMedGoogle Scholar
  3. 3.
    Rinehart K, Gloer J, Hughes R, Renis H, McGovren J, Swynenberg E, Stringfellow D, Kuentzel S, Li L: Didemnins: Antiviral and antitumor depsipeptides from a Caribbean tunicate. Science 212:933–935, 1981PubMedGoogle Scholar
  4. 4.
    Chun H, Davies B, Hoth D, Suffness M, Plowman J, Flora K, Grieshaber C, Leyland-Jones B: Didemnin B. The first marine compound entering clinical trials as an antineoplastic agent. Invest New Drugs 4:279–284, 1986PubMedGoogle Scholar
  5. 5.
    Montgomery D, Zukoski C: Didemnin B: A new immunosuppressive cyclic peptide with potent activityin vitro andin vivo. Transplantation 40:49–56, 1985PubMedGoogle Scholar
  6. 6.
    Dorr F, Kuhn J, Phillips J, Von Hoff D: Phase I clinical and pharmacokinetic investigation of didemnin B, a cyclic depsipeptide. Eur J Cancer Clin Oncol 24:1699–1706, 1988PubMedGoogle Scholar
  7. 7.
    Motzer R, Scher H, Bajorin D, Sternberg C, Bosl G: Phase II trial of didemnin B in patients with advanced renal cell carcinoma. Invest New Drugs 8:391–392, 1990PubMedGoogle Scholar
  8. 8.
    Taylor S, Piston B, Stevens R, Crawford E: Phase II trial of didemnin B in advanced adenocarcinoma of the kidney: Southwest Oncology Group study. Proc Am Soc Clin Oncol 8:564, 1989, abstractGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1992

Authors and Affiliations

  • Dennie V. JonesJr.
    • 1
  • Jaffer A. Ajani
    • 1
  • Roxann Blackburn
    • 1
  • Karen Daugherty
    • 1
  • Bernard Levin
    • 1
  • Yehuda Z. Patt
    • 1
  • James L. Abbruzzese
    • 1
  1. 1.Section of Gastrointestinal Oncology, Department of Medical Oncology, Division of MedicineUniversity of Texas M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations